160 related articles for article (PubMed ID: 23877991)
21. Long-term outcomes of analogue insulin compared with NPH for patients with type 2 diabetes mellitus.
Prentice JC; Conlin PR; Gellad WF; Edelman D; Lee TA; Pizer SD
Am J Manag Care; 2015 Mar; 21(3):e235-43. PubMed ID: 26014311
[TBL] [Abstract][Full Text] [Related]
22. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
[TBL] [Abstract][Full Text] [Related]
23. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
Rhoads GG; Kosiborod M; Nesto RW; Fonseca VA; Lu SE; Zhang Q; Foody JM
Am J Cardiol; 2009 Oct; 104(7):910-6. PubMed ID: 19766755
[TBL] [Abstract][Full Text] [Related]
24. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
25. Treatment persistence in the use of basal insulins in Poland and Germany
.
Rathmann W; Czech M; Franek E; Kostev K
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):119-125. PubMed ID: 27879196
[TBL] [Abstract][Full Text] [Related]
26. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis.
Dejgaard A; Lynggaard H; Råstam J; Krogsgaard Thomsen M
Diabetologia; 2009 Dec; 52(12):2507-12. PubMed ID: 19838665
[TBL] [Abstract][Full Text] [Related]
27. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
28. [Switching of NPH insulin to glargine therapy in a cohort of diabetic patients: observational study].
Maia FF; Melo FJ; Araújo IM; Araújo LR
Arq Bras Endocrinol Metabol; 2007 Apr; 51(3):426-30. PubMed ID: 17546241
[TBL] [Abstract][Full Text] [Related]
29. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.
Frier BM; Russell-Jones D; Heise T
Diabetes Obes Metab; 2013 Nov; 15(11):978-86. PubMed ID: 23551900
[TBL] [Abstract][Full Text] [Related]
30. Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study.
Chang CH; Toh S; Lin JW; Chen ST; Kuo CW; Chuang LM; Lai MS
PLoS One; 2011; 6(6):e21368. PubMed ID: 21738645
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
[TBL] [Abstract][Full Text] [Related]
32. Long-term effects of insulin glargine on the risk of breast cancer.
Suissa S; Azoulay L; Dell'Aniello S; Evans M; Vora J; Pollak M
Diabetologia; 2011 Sep; 54(9):2254-62. PubMed ID: 21614572
[TBL] [Abstract][Full Text] [Related]
33. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
Blin P; Lassalle R; Dureau-Pournin C; Ambrosino B; Bernard MA; Abouelfath A; Gin H; Le Jeunne C; Pariente A; Droz C; Moore N
Diabetologia; 2012 Mar; 55(3):644-53. PubMed ID: 22222504
[TBL] [Abstract][Full Text] [Related]
34. Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.
Varewijck AJ; Yki-Järvinen H; Schmidt R; Tennagels N; Janssen JA
Diabetes; 2013 Jul; 62(7):2539-44. PubMed ID: 23569175
[TBL] [Abstract][Full Text] [Related]
35. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
[TBL] [Abstract][Full Text] [Related]
36. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.
Eliaschewitz FG; Calvo C; Valbuena H; Ruiz M; Aschner P; Villena J; Ramirez LA; Jimenez J;
Arch Med Res; 2006 May; 37(4):495-501. PubMed ID: 16715577
[TBL] [Abstract][Full Text] [Related]
37. Different persistence on initial basal supported oral therapy in Type 2 diabetics is associated with unequal distributions of insulin treatment regimens under real-life conditions in Germany.
Pfohl M; Dippel FW; Kostev K; Fuchs S; Kotowa W
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):761-6. PubMed ID: 20979936
[TBL] [Abstract][Full Text] [Related]
38. Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients.
Hendriksen KV; Jensen T; Oturai P; Feldt-Rasmussen B
Diabetologia; 2012 Jan; 55(1):46-50. PubMed ID: 22002075
[TBL] [Abstract][Full Text] [Related]
39. Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin.
Fiesselmann A; Wiesner T; Fleischmann H; Bramlage P
Acta Diabetol; 2016 Oct; 53(5):717-26. PubMed ID: 27093968
[TBL] [Abstract][Full Text] [Related]
40. Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice.
Nagel JM; Staffa J; Renner-Müller I; Horst D; Vogeser M; Langkamp M; Hoeflich A; Göke B; Kolligs FT; Mantzoros CS
Horm Cancer; 2010 Dec; 1(6):320-30. PubMed ID: 21761363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]